Determinants of omalizumab drug survival in a long‐term daily practice cohort of patients with chronic urticaria

Spekhorst, Lotte S; Reek, J.M.P.A. van den; Knulst, André C.; Röckmann, Heike

doi:10.1111/all.13714

Cited by 9 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Danish study reported that 56% of CSU patients were on treatment after 1 year. 26 These results are similar to our results. We could not discontinue the treatment in 14 patients.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

The effect of at least 1‐year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria

Bahalı

Onsun

2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…A Danish study reported that 56% of CSU patients were on treatment after 1 year. 26 These results are similar to our results. We could not discontinue the treatment in 14 patients.…”

Section: Discussionsupporting

confidence: 93%

“…In a study of 298 patients in the US, more than 70% of patients remained on OMA treatment for at least 1 year. A Danish study reported that 56% of CSU patients were on treatment after 1 year 26 . These results are similar to our results.…”

Section: Discussionsupporting

confidence: 92%

The effect of at least 1‐year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria

Bahalı

Onsun

2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…[32][33][34][35] Recently, other monoclonal antibodies targeting type 2 inflammation 36 have been approved and are available now for patients with eosinophilic asthma, 37-41 atopic dermatitis, 42,43 and urticaria. 36,[42][43][44][45][46] A number of trials have been done with biological therapies for CRSwNP. [47][48][49][50] As these drugs enter the market, it necessitates the medical community to reflect on the positioning of these therapies in the current care pathways of the upper and lower airways.…”

Section: Introductionmentioning

confidence: 99%

EUFOREA consensus on biologics for CRSwNP with or without asthma

Fokkens

Lund

Bachert

et al. 2019

Allergy

281

288

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. AbstractNovel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of | 2313 FOKKENS Et al.

show abstract

“…19 Recently, the drug survival of omalizumab has been studied in an adult Dutch CU population. 20 This study showed a 1-, 2-and 3-year overall drug survival of omalizumab of 77%, 61%, and 55%, respectively, mostly determined by well-controlled disease activity, demonstrating high safety and effectiveness in daily practice. 20 In pediatric patients with CU, however, daily practice data of treatment with omalizumab are lacking.…”

Section: Introductionmentioning

confidence: 61%

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

Dekkers

Aghdam

Graaf

et al. 2021

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

Background: Evidence on safety and effectiveness of omalizumab for treatment of chronic urticaria in pediatric patients is scarce and limited to case reports. In particular, drug survival of omalizumab has not yet been investigated, which is a key element in the evaluation of its clinical performance. The aim of this study was to investigate safety, effectiveness, and drug survival rates of omalizumab in a daily practice cohort of pediatric patients with chronic urticaria (CU).Methods: This is a multicenter study including all pediatric patients from an academic center (Wilhelmina Children's Hospital) and a general center (Diakonessenhuis Hospital) in the Netherlands, who started omalizumab treatment before the age of 18 years. Data on safety, effectiveness, time to discontinuation, and reasons for discontinuation of treatment were assessed. Drug survival of omalizumab was estimated using the Kaplan-Meier survival analysis.Results: A total of 38 patients, who started treatment between January 2014 and January 2020, were included. Most patients (68.4%) used omalizumab without reporting any side effects and a complete or good response to treatment was achieved in 76.3% of patients. The 1-and 2-year drug survival rates were 62% and 50%, respectively, with well-controlled disease activity as the most frequent reason for discontinuation in 69.2% of patients, followed by ineffectiveness in 23.1% and side effects in 7.7% of patients. Conclusions:This study demonstrates high safety and effectiveness of omalizumab treatment in pediatric patients with CU, which will aid clinical decision making and management of expectations when choosing omalizumab treatment for pediatric patients with CU.

show abstract

Determinants of omalizumab drug survival in a long‐term daily practice cohort of patients with chronic urticaria

Cited by 9 publications

References 10 publications

The effect of at least 1‐year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria

The effect of at least 1‐year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria

EUFOREA consensus on biologics for CRSwNP with or without asthma

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

Contact Info

Product

Resources

About